The clinical response to TNFi is attenuated by obesity, an effect that is less evident with IL-6 inhibitors and rituximab, and negligible with abatacept [reviewed (38)]. The gene discussed is IL6; the disease is obesity due to melanocortin 4 receptor deficiency.